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Ornithine transcarbamylase deficiency (OTCD) is a rare X-linked disorder of urea synthesis leading to hyperammonemia.
Several late-onset cases have been reported. Undiagnosed and untreated patients are at the risk of death or suffering from
irreversible sequelae. We describe a 56-year-old patient who presented with acute encephalopathy after steroid treatment.
Hyperammonemia due to OTCDwas diagnosed and a mutation was found.This allowed us to diagnose two other family members
with unexplained encephalopathywho are nowasymptomatic on a low-protein diet.OTCDshould be considered in any patientwith
hyperammonemic encephalopathy and immediate treatment should be given to avoid a fatal outcome. We emphasize the need to
examine other familymembers if the diagnosis is confirmed, in order to prevent further life-threatening episodes of encephalopathy
or neonatal coma of newborn.
1. Introduction
Ornithine transcarbamylase deficiency (OTCD) is a rare X-
linked disorder of urea synthesis leading to hyperammone-
mia [1] that usually presents in newborn. An increasing
number of late-onset cases have been reported in adults, most
of them females [2, 3] with symptom onset coinciding with a
precipitating factor [4]. However, in some cases the trigger
cannot be identified [5]. Without treatment patients may die
or suffer from irreversible cognitive sequelae [1]. It is therefore
crucial to identify these late-onset patients and to test the rest
of the family if a mutation is found.
2. Case Presentation
A previously healthy 56-year-old Spanish man was admitted
due to acute disorientation and agitation. He had suffered a
common cold 3 weeks before. Four days prior to admission
he had received a steroid injection to treat his knee arthritis.
He had a decreased level of consciousness (Glasgow Coma
Scale 9) but a normal physical examination. He required
sedation and orothracheal intubation. Blood tests revealed
mild leukocytosis (14,46 × 109/L) and high ammonium levels
(320 𝜇g/dL), with normal pH, liver, and renal function, nega-
tive serologies and antibodies (HSV,HIV, autoantibodies, and
antineuronal antibodies), and normal CSF (biochemistry,
cell count, HSV PCR, culture). Brain CT and MR were
normal. EEG showed a severe encephalopathy with acute
bifrontal activity. A mycoplasma serology was positive and
parainfectious encephalitis was suspected because of the
previous cold. A urea cycle disorder triggered by drugs was
also considered and amino acids weremeasured in blood and
urine, showing no relevant abnormalities. Urine orotic acid
was not measured. The clinical picture and the ammonium
levels resolved after hemodialysis.
Two months later he underwent a laser cordotomy and
required steroid treatment because of glottic edema. Four
days later he developed progressive encephalopathy and
required orothracheal intubation again. Blood tests revealed
hyperammonemia and leukocytosis; the rest of the blood
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Figure 1: Family tree. Subjects 𝑥 and 𝑦 are affected carriers. Subject 𝑧 has two carrier daughters and is suspected to have been an affected
carrier.
and CSF tests were again normal. OTCD was suspected
and DNA analysis revealed a c.622G>A (p.A208T) mutation.
The patient improved after hemodialysis and has remained
asymptomatic.
Other family members were studied (Figure 1). Two of
them had been suffering from episodes of encephalopathy
and could be finally diagnosed. Subject 𝑥 (brother) is a 55-
year-old male, who had complained of excessive somnolence
aftermeals for 3 years previously, which resolved after starting
a low-protein diet; he was recently admitted because of
hyperammonemic encephalopathy triggered by infection and
steroid treatment, which resolved after hemodialysis. He
had a normal basal amino acid profile and urine orotic
acid. The diagnosis was genetically confirmed. Subject 𝑦
(nephew) had suffered several episodes of hyperammonemic
encephalopathy from the age of 13; the first episode had been
attributed to metoclopramide, the following one to juvenile
epilepsy, and the last ones to azathioprine treatment for
Crohn’s disease. Since OTCD was confirmed two years ago,
he has followed a low-protein diet. He has normal ammonia
and amino acid levels and has not suffered any other episodes.
Subject 𝑧 (brother) had died with encephalopathy and brain
edema of an unknown cause. He was a donor and his liver
was rejected for transplantation because of its pathological
macroscopic appearance. His two daughters are mutation
carriers, but not his wife, so the patient must have been
affected.
3. Discussion
Patients with late-onset OTCD are frequently misdiagnosed
as encephalitis, poisoning, psychotic illness, or epilepsy. A
personal or family history of similar episodes and precipi-
tating factors should be investigated [4]. Hyperammonemia
can be triggered by high protein intake, increased protein
catabolism due to infection, trauma, physical exercise or
steroids, hepatic toxicity from chemotherapy and other
medications, pancreatitis, or postpartum [5–8]. There are
at least five reports of OTCD adults who developed acute
hyperammonemic coma following steroid administration
[3, 6, 9–11]. Glucocorticoids are known to have a general
catabolic effect by primarily enhancing protein turnover [12].
Ammonia should be measured in patients of any age
presenting an unexplained encephalopathy and a urea cycle
defect should be suspected if the patient has a normal
liver function. Elevated glutamine and alanine plasma levels,
decreased citrulline, and presence of orotic acid in the urine
are usually found in OTCD [13], but these can be within
normal range in the compensated state, as was the case of
subject 𝑥.These tests should be performed in the acute phase,
and if this is not possible, samples should be frozen for further
testing. Regardless of the results, if the suspicion of OTCD is
high, a genetic analysis should be performed.
Mutation analysis is the method of choice for the defini-
tive diagnosis. In the majority of patients the mutation
appears de novo (mother not carrier). In almost 20% of
OTCD patients the mutation is not identified [14, 15]; OTC
enzyme activity assay in liver or intestinal mucosa can help
in such cases. The measure of urinary orotidine excretion in
women after the administration of a single dose of allopurinol
(allopurinol challenge test) is also a simple and reliable
method of assigning carrier status to women suspected of
carrying a mutation [16].
A review in 2006 identified 341 mutations of the OTC
gene [15] and new ones are being discovered (http://www
.biobase-international.com/product/hgmd). The mutation
found in our family has been already reported in other
families [17, 18], with a variable age of onset and presentation,
from asymptomatic to fatal coma.
Hemodialysis is the treatment of choice for rapid reduc-
tion of ammonia levels in adults and should be started
quickly, even before confirming the diagnosis, in order to
prevent intracranial hypertension and cerebral edema. Other
measures include intravenous hydration with glucose and
lipids, ammonia scavengers, L-arginine, and cessation of
protein intake [6, 19]. Long-term management is based on a
low-protein diet. Liver transplantation may be considered in
selected patients [14].
The possibility of an OTCD should be considered in any
patient with hyperammonemic encephalopathy and treated
rapidly to avoid fatal coma or long-term cognitive sequelae.
We emphasize the importance of measuring ammonia and
considering the diagnosis of urea cycle disorders in any
patient with encephalopathy.The other familymembers need
to be examined if the diagnosis is confirmed because it is
a treatable condition and therefore further life-threatening
episodes of encephalopathy or neonatal coma of the newborn
can be appropriately prevented and rapidly treated.
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